CAVE CREEK, AZ--(Marketwired - Jun 22, 2016) - Endexx Corporation (OTC PINK: EDXC), a provider of innovative hemp derived phyto-nutrients and nutritional health products, announced today that approximately 40 patients have enrolled in an adaptive clinical study to test the efficacy of its proprietary CBD capsule in alleviating symptoms for patients suffering from neuropathic pain.
The clinical trial, conducted at four sites by four physicians, is an extension of the work conducted by Dr. Daniel Kiddy and a follow up of Dr. Daniel Brandwein who will enroll up to eighty 80 patients into four groups of twenty, for a one-month study using CBD enriched capsules to evaluate neuropathic pain reduction. The proprietary formulations are manufactured in a regulated compound pharmacy and designed by the doctor and pharmacist. The formulated and manufactured capsules utilized in this study include a dual pack as a day and night formula with cannabidiol as its primary active ingredient. Each patient will be taking two capsules a day with results to be monitored. At the end of the study, findings will be subjected to an independent peer review board.
Early indications suggest continued benefits. Dr. Daniel Brandwein stated, "After two weeks of usage, patients are reporting an improvement in their neuropathy. One patient with type 1 diabetes suffering from general numbness and pain in her feet reported after 2 weeks the numbness was now limited to her toes." Dr. Daniel Kiddy commented, "We are encouraged with early results of the CBD capsules being tested. Early findings have shown the effectiveness of the capsule is equal to if not greater than pain relief found via the sublingual delivery method. All four physicians have started trials and results will be evaluated within the next three to four weeks."
Todd Davis, CEO of Endexx said, "We are excited that this study is underway and eager to see the results once it is completed."
Endexx provides innovative medical marijuana management and technology solutions. Endexx, with its collaborative partners and consultants, develops and distributes consumable product lines derived from industrial hemp that is GMO and pesticides free and naturally rich in phytocannabinoids. The company has two technology products and services that launched in 2014 -- the M3hub and the Autospense™. Both products provide essential solutions to promote regulatory compliance and full accountability through "seed to sale" inventory management and tracking. Based on principles developed by the pharmacological industry, the m3hub platform is the first standardized software solution for tracking pharmaceutical grade marijuana that maintains compliance with federal, state and local regulations. It is intended to provide a smooth transition to an eventual federal mandates. The Autospense™ is a high-tech marijuana inventory control and dispensing device that provides up-to-the-minute accounting details and ensures both product and patient security. By automating the dispensing process, Autospense™ increases productivity and reduces costs for marijuana retailer, while enhancing their service quality by reducing transaction time for customers. Websites include: www.cbdunlimited.com, www.cbdhealthsolutions.com, www.endexx.com, www.m3hub.com.
Safe Harbor Notice
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Security and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.